Table 1.
Baseline patient characteristics
| Characteristic | n = 8, n (%) |
|---|---|
| Histology | |
| MCL | 8 (100) |
| Age, median (IQR) | 67.0 (62.8-71.0) |
| Sex | |
| Female | 2 (25) |
| Male | 6 (75) |
| Stage | |
| 3 | 1 (12) |
| 4 | 7 (88) |
| Prior lines of therapy | |
| 1 | 8 (100) |
| Prior ibrutinib | 1 (12) |
| Prior stem cell transplant | 0 (0) |
| KI 67 at enrollment | |
| <30% | 2 (25) |
| ≥30% | 6 (75) |
| Histology | |
| MCL, NOS | 3 (38) |
| MCL, blastoid variant | 4 (50) |
| MCL, pleomorphic variant | 1 (12) |
| LDH at enrollment above ULN | 4 (50) |
| Lesion >5 cm | 3 (38) |
| Number of extranodal sites | |
| <2 | 4 (50) |
| ≥2 | 4 (50) |
| Baseline SUV max, median (IQR) | 14 (8-26) |
| TP53 deletion at enrollment* | 3 (38) |
| TP53 mutation at enrollment* | 5 (62) |
LDH, lactate dehydrogenase; NOS, not otherwise specified; SUV, standardized uptake value.
*
One patient's MCL had both a TP53 mutation and TP53 deletion.